LVBH107 Antibacterial Activity against and Anti-Inflammatory Activity against Lipopolysaccharide-Stimulated RAW 264.7 Cells.

Probiotics, active microorganisms benefiting human health, currently serve as nutritional supplements and clinical treatments. Periodontitis, a chronic infectious oral disease caused by (), activates the host immune response to release numerous proinflammatory cytokines. Here, we aimed to clarify () LVBH107 probiotic effects based on the inhibition of activities while also evaluating the effectiveness of an in vitro lipopolysaccharide-stimulated RAW 264.7 cell-based inflammation mode. LVBH107 survived at acid, bile salts, lysozyme, and hydrogen peroxide conditions, auto-aggregated and co-aggregated with , exhibited strong hydrophobicity and electrostatic action, and strongly adhered to gingival epithelial and HT-29 cells (thus exhibiting oral tissue adherence and colonization abilities). Moreover, LVBH107 exhibited sensitivity to antibiotics erythromycin, doxycycline, minocycline, ampicillin, and others (thus indicating it lacked antibiotic resistance plasmids), effectively inhibited biofilm formation and inflammation (in vitro inflammation model), reduced the secretion of pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and inflammatory mediators (NO and PGE), and decreased the expression levels of inflammation related genes. Thus, LVBH107 holds promise as a probiotic that can inhibit biofilm formation and exert anti-inflammatory activity to maintain oral health.